Healthcare >> CEO Interviews >> November 2, 2026
Dikla Czaczkes Akselbrad serves as the Chief Executive Officer of PolyPid Ltd. after serving as the company’s EVP and CFO since 2017, leading the company’s initial public offering on the Nasdaq Global Market in June 2020. Ms. Akselbrad brings more than 20 years of experience leading life sciences companies through critical international strategic, financial and business transitions, including raising over $350 million in various forms in her prior executive roles. Before joining PolyPid in 2014, Ms. Akselbrad served as CFO of Compugen Ltd. (NASDAQ & TASE:CGEN) after serving as CFO of Packet Technologies Ltd., and an audit manager at Ernst & Young Israel. She received a B.A. in accounting and economics and an MBA from Tel-Aviv University, and is a certified public accountant in Israel. Profile
Word count: 3,304
TWST: This is the first time we’re speaking to your company, PolyPid. PolyPid is a biotech company. Your flagship product is D-PLEX100, designed to aid
